Work

Team Work Matters: Dual Inhibition Puts Non-Hodgkin Lymphoma Under Siege

Year: 2014

Type: article

Abstract: Inhibitors of PI3K/mTOR and histone deacetylases (HDAC) are effective in non-Hodgkin lymphoma (NHL). However, clinical resistance eventually ensues and combinatory therapies are sought to prevent it. Preclinical evaluation of dual PI3K/mTOR and HDAC inhibition is synergistic against NHL, paving the way for bench-to-bedside translation.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-14-2055

Authors: Giada Bianchi, Irene M. Ghobrial

Institutions: Harvard University, Dana-Farber Cancer Institute

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute